Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Ascelia Pharma completes a directed new share issue of 4,697,781 shares, raising approximately SEK 98.7 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has, based on the authorisation granted by the annual general meeting on 6 May 2020, resolved on a directed new share issue to selected Swedish and international institutional

Scandion Oncology co-founders extend lock-up period

Scandion Oncology A/S (“Scandion Oncology”) announces that its two co-founders, CEO Nils Brünner and CSO Jan Stenvang, have extended the lock-up period for their Scandion Oncology shares with an additional three months (until October 1, 2020). In total, the lock-up agreements correspond to approximately 13 percent of the votes and capital in Scandion Oncology.CEO Nils Brünner and CSO Jan Stenvang have signed and prolonged the lock-up agreements for their shares with three months. The two co-founders commit to retain 90 percent of their holdings in the company until October 1, 2020. The

Leading Edge Materials to Participate in Graphite and Graphene Anode Research Project

Vancouver, BC, June 30, 2020 /CNW/ – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) announces the participation of its subsidiary Woxna Graphite AB in the newly launched research project “Graphite and graphene as battery electrodes” (the “Project”) which is part of the Vinnova funded competence centre Batteries Sweden (“BASE”). The Project will research the utilization of natural graphite for battery applications through determination of functionality of the natural graphite in batteries, the addition of

EQT sets target fund size for EQT Infrastructure V at EUR 12.5 billion

EQT has today set the target size for the EQT Infrastructure V fund at EUR 12.5 billion. The actual fund size is dependent on the outcome of the fundraising process and may ultimately be higher or lower than the target size. The EQT Infrastructure V fund’s investment strategy and commercial terms are expected to be materially in line with predecessor fund, EQT Infrastructure IV. To ensure continuity between two fund generations, EQT’s capital raisings usually follow a cycle with successor funds generally targeted to be in a position to commence investment activities when the predecessor

Changes in the number of shares and votes in Betsson AB (publ)

As at 18 June 2020, the total number of shares in Betsson AB (publ) (the “Company”) amounts to 288,986,476 shares, divided into: 31,822,000 class A shares; 245,009,460 class B shares and 12,155,016 class C shares. The total number of votes in the Company as at 18 June 2020 amounts to 575,384,476. At the Annual General Meeting held on 11 June 2020, one of the Company’s resolved resolutions was to carry out an automatic share redemption scheme by increasing the number of shares and votes in a share split (2:1). The number of shares and votes will be restored after the redemption is

Sweden’s vegan algae pioneer Simris to raise SEK 29 million through rights issue

Simris (FNSE: SIMRIS) is a pioneering agribusiness growing algae. Its purpose is to save and protect endangered marine habitats, by producing ingredients from farmed microalgae instead of fish and other marine animals. Following successful expansion to full industrial scale and first market milestones, the company is raising capital to support its launch on the US market. Last date of the subscription period is 8 July 2020.Simris is a multi-awarded innovation-based company and pioneers in the development of microalgae as a novel crop and biotechnological production platform. The purpose of

Change of number of shares and votes in Instalco

Pursuant to the Swedish Financial Instruments Trading Act (Sw. lagen (1991:980) om handel med finansiella instrument), Swedish companies whose shares are listed on a regulated market and who increases or reduces the total number of shares or votes in the company is to disclose such changes on the last trading day the same month.As of 30 June 2020, there are in total 50 474 022 shares and votes in Instalco AB (“Instalco” or the “Company”). The change in number of shares and votes in the Company is a result of the board of directors’ decision to issue in total 79 693 new shares within the

Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, CSO, replacing MD Christian Jacques who has held the position as CSO since 2018. Christian will continue as a Senior Advisor. .Marty J Duvall brings extensive global commercialization skills from executive leadership roles in pharma and

Change in the number of shares and votes in Scandic

The number of shares and votes in Scandic Hotels Group AB (publ) (“Scandic”) has changed in June 2020 as a result of the rights issue previously announced. The total number of shares in Scandic has in June 2020 increased by 86,907,312 shares, corresponding to 86,907,312 votes. Today, the last trading day of the month, the total number of shares and votes in Scandic amounted to 189,892,387.  The rights issue comprises a total of 88,272,918 shares, of which the remaining 1,365,606 shares will be registered at the Swedish Companies Registration Office in July 2020. For more

Board election in DNB ASA

The Annual General Meeting of DNB ASA was held on 30 June 2020. At the Annual General Meeting, Svein Richard Brandtzæg and Jens Petter Olsen were elected as new board members with a term of office of up to two years. Olaug Svarva was re-elected as Chair of the Board and Jaan Ivar Semlitsch was re-elected as a board member, both with a term of office of up to two years. The Board of Directors of DNB ASA now has the following members: Olaug Svarva (Chair of the Board) - 2022Svein Richard Brandtzæg (Vice Chair of the Board) - 2022Jens Petter Olsen - 2022Jaan Ivar Semlitsch - 2022

DNB ASA – Annual General Meeting held on 30 June 2020

DNB’s Annual General Meeting was held on 30 June 2020. The Annual General Meeting was held digitally as a result of the measures introduced due to the COVID-19 outbreak. All items on the agenda were adopted as proposed, cf. the notice published on 8 June 2020, including the following: The Annual General Meeting gave the Board of Directors authorisation to raise subordinated loans and other debt capital, cf. section 11-2 of the Financial Institutions Act, for a total value of up to NOK 20 billion, or the equivalent in foreign currency.  The minutes from the Annual General Meeting

Nyfosa has announced that the financing condition regarding SBB's sale of properties for SEK 4.9bn to Nyfosa has been resolved

As previously announced, on 10 June 2020, Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) signed an agreement for the sale of office properties totalling SEK 4.9bn to Nyfosa AB (“Nyfosa”). The transaction is conditional upon financing and approval from the Swedish Competition Authority (the “Competition Authority”). Nyfosa has today announced that they have acquired necessary bank loans, therefore the financing condition is resolved. A positive Competition Authority approval is expected during July. Closing is scheduled to take place as soon as possible after the Competition

Observe Medical ASA – Primary insider notice

Reference is made to the ongoing rights issue of 4,090,909 new shares (the "Offer Shares") at a subscription price of NOK 11.00 per share in Observe Medical ASA (the "Company") as announced in the Company's stock exchange announcement on 19 June 2020 (the "Rights Issue"). Primary insider, Kathrine Gamborg Andreassen, a member of the Company's board of directors, has today, on 30 June 2020, through her wholly-owned company Soleglad Invest AS, sold 144,428 subscription rights to subscribe for Offer Shares in the Rights Issue at a price of NOK 1.60 per subscription right. Following the

Number of shares and votes in Calliditas Therapeutics

During June, Calliditas Therapeutics AB (publ) has issued 9,230,770 common shares as a result of the initial public offering on The Nasdaq Global Select Market in the United States and concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States. Thus, as of June 30, 2020, the number of shares and votes in the Company amounts to 47,938,408. For further information, please contact: Renée Aguiar-Lucander, CEO at Calliditas Tel.: +46 722 52 10 06, email: renee.lucander@calliditas.com Mikael

Financing secured for Nyfosa’s acquisition of property portfolio for SEK 4.9 billion

As previously announced, Nyfosa signed an agreement on June 10, 2020 for the acquisition of a property portfolio comprising mainly tax-funded tenants at a value of SEK 4.9 billion from SBB i Norden AB.The transaction is conditional upon financing and the approval of the Swedish Competition Authority. Nyfosa’s financing has now been secured by raising new bank loans. A favorable ruling is anticipated from the Swedish Competition Authority, which is expected to be issued in July. Closing is scheduled to take place as soon as possible following approval by the competition authority and not

European Lingerie Group AB announces delay in delivery of annual report 2019

On 29 April 2020 European Lingerie Group AB (the "Company" and together with its subsidiaries from time to time, the “Group”) announced that it would not be able to deliver its annual audited financial statements for the year 2019 on or prior to 30 April 2020 as previously communicated in its reporting calendar due to uncertainty related to Covid-19 situation and its impact on the financial position of the Company. Furthermore, the Company announced, that it has ongoing discussions with certain holders of the Bonds and other investors to find solutions for the Group which are required to be

Magnolia Bostad and Heimstaden develops homes in Skellefteå

Magnolia Bostad signs an agreement to sell the Västra Erikslid project in Skellefteå municipality to Heimstaden Bostad. The project involves the development of approximately 300 residential units of 21,000 sq.m. GFA. Estimated property value at completion is about SEK 475 million.The sale concerns part of the Skellefteå 5:1 property in Västra Erikslid, in which Magnolia Bostad won a land allocation competition in March 2020. The project has a zoning plan in force and turnkey contract is signed with Derome. The sale takes place as a company transfer with estimated occupancy at the end of

Result of Bondholders’ Meeting

We refer to summons dated 16 June 2020, issued at the request of bondholders holding in excess of 10% of the DOFSUB07, to consider the appointment of new advisors in connection with the contemplated financial restructuring of the Issuer and its subsidiaries. In a bondholders' meeting held today 30 June 2020, the proposal to change advisors did not get the votes required under the bond agreements. See enclosed Result of the meeting on 30 June 2020. For further information, please contact: Mons S. Aase, CEO Tel: +47 91 66 10 12 Hilde Drønen, CFO Tel: +47 91 66 10 09

#20-227 Delisting of certain Derivatives from NGM

Certain derivatives will be delisted from NGM.For more details see attached files. For further information concerning this NGM notice please contact: Listing department on +46 8 566 390 20 or at listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

#20-226 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

The Enduring, Historic Charm of California’s Oldest Hotels

SACRAMENTO, CA [June 30, 2020]—Some of California’s oldest hotels in the state have survived fires, earthquakes, pandemics, the Great Depression, and various cycles of neglect and renewal. While the current pandemic has left few destinations unscathed, these enduring hotels will no doubt enchant travelers with their historic charms once again. 1859 Historic National HotelIn the Gold Rush town of Jamestown, the 1859 Historic National Hotel  has been in nearly continuous operation since it was first built. Stephen Willey is only the third owner of the

Employers facing tough decisions over redundancies as furlough changes loom

EMPLOYERS are facing tough decisions over redundancies as they consider what furlough changes will mean for their businesses. The government’s furlough scheme becomes more flexible on July 1 with a change designed to help businesses start to ease back into operation after lockdown. But for many business owners it’s the looming increased contributions they need to make to the scheme, which take effect a month later on August 1, that are keeping them awake at night. Joanne Stronach, Head of Employment Law at leading legal firm Cartmell Shepherd Solicitors, says the prospect of having

KAYDENCE PHARMA UPDATE

Oslo, Norway (30 June 2020) At the Annual General Meeting (“AGM”) today of Kaydence Pharma AS (“Kaydence Pharma”) it has been decided that NattoPharma ASA (“NattoPharma”) will convert NOK 4 million of its loans to equity in Kaydence Pharma. The loan will be converted at NOK 5 per share giving NattoPharma a total number of 3 000 000 shares representing a 54.15% interest as at 30 June 2020. Following the conversion, NattoPharma´s loan to Kaydence Pharma is NOK 51 million. Further the AGM decided that the Board of Kaydence Pharma has been replaced with Kjetil Ramsøy as Chairman of the

Aptahem’s collaboration with Örebro University further increases the understanding of Apta-1

Aptahem (publ) is a biotech company developing aptamer-based pharmaceuticals for the treatment of life-threatening conditions, such as sepsis. A similar mechanism occurs in cardiovascular diseases where a combination of coagulation and inflammation are involved. Aptahem today announces that the collaboration with the Cardiovascular Research Centre (CVRC) at Örebro University with funding from the Knowledge Foundation’s Prospect Call now has generated its first results. Preliminary data confirm the previously known anti-inflammatory and non-toxic properties of Apta-1 and also show new insights

There are no items matching the current filter
There are no more items matching the current filter
Back to top